Evaluation of TQ-B3234 Capsules in Patients With Symptomatic, Non-Surgical Type 1 Neurofibromatosis-Associated Plexiform Neurofibromas
A phase 3 trial testing TQ-B3234 in rare cancers of childhood, now recruiting.
Overview
Evaluation of TQ-B3234 Capsules in Patients With Symptomatic, Non-Surgical Type 1 Neurofibromatosis-Associated Plexiform Neurofibromas is a phase 3 interventional study registered as NCT07407803, led by Chia Tai Tianqing Pharmaceutical, and recruiting when checked on 2026-09-11. Official title: Randomised, Double-Blind, Parallel-Controlled, Multicenter Phase III Clinical Trial Evaluating the Efficacy and Safety of TQ-B3234 Capsules Versus Placebo in Patients With Symptomatic, Non-Surgical Type 1 Neurofibromatosis-Associated Plexiform Neurofibromas. Planned enrolment is 177 participants (estimated). The study started in 2026-03-31 and primary completion is expected in 2027-12. No results have been posted on ClinicalTrials.gov.
Similar pages
not linked directly; found by shared links- TrialA Clinical Trial of TQB2102 for Injection in the Treatment of HER2 Low-Expressing Recurrent/Metastatic Breast Cancer
Shares Sino Biopharmaceutical (Chia Tai Tianqing) and the tag ctgov-ingest.
- TrialA Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule Versus Sunitinib in Subjects With Advanced Renal Cancer
Shares Sino Biopharmaceutical (Chia Tai Tianqing) and the tag ctgov-ingest.
- TrialTo Evaluate the Efficacy and Safety of TQB3616 in Combination With Fulvestrant Versus Placebo in Combination With Fulvestrant in Previously Untreated Hormone-receptor (HR)-Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Advanced Breast Cancer
Shares Sino Biopharmaceutical (Chia Tai Tianqing) and the tag ctgov-ingest.
- TrialClinical Study on Adjuvant Therapy of TQB3616 Combined With Endocrine Therapy Compared With Placebo Combined With Endocrine Therapy in Patients With Breast Cancer
Shares Sino Biopharmaceutical (Chia Tai Tianqing) and the tag ctgov-ingest.
- TrialA Study of AL2846 Capsule Versus Placebo in the Treatment of Advanced Radioiodine-Refractory Differentiated Thyroid Carcinoma
Shares Sino Biopharmaceutical (Chia Tai Tianqing) and the tag ctgov-ingest.
- TrialA Clinical Study of TQB2102 Versus Docetaxel Plus Trastuzumab and Pertuzumab in the Treatment of HER2 Positive Recurrent or Metastatic Breast Cancer
Shares Sino Biopharmaceutical (Chia Tai Tianqing) and the tag ctgov-ingest.
- TrialClinical Trial of TQB2102 for Injection Versus Trastuzumab Emtansine for Injection in HER2-positive Advanced Breast Cancer
Shares Sino Biopharmaceutical (Chia Tai Tianqing) and the tag ctgov-ingest.
- TrialA Clinical Study of Neoadjuvant Treatment With TQB2102 for Injection for Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer
Shares Sino Biopharmaceutical (Chia Tai Tianqing) and the tag ctgov-ingest.